Second Mucodis® Medical Device Launch

Quantum Pharma Plc

("Quantum" or the "Group")

Second Mucodis® Medical Device Launch

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the launch of Mucodis® mouthwash by Colonis, part of its Niche Pharmaceuticals division. Mucodis® mouthwash is the fifth regulated product to be launched by Colonis and the second in a range of Mucodis® branded medical devices to treat some of the side effects of cancer treatments in patients

The mouthwash has been developed to prevent oral mucositis, one of the most common and debilitating complications of chemotherapy and radiation. Mucositis can lead to several problems including pain, nutritional problems resulting from the inability to eat, and increased risk of infection due to open sores in the lining of the mouth. It has a significant effect on the patient's quality of life and can affect the patient's ability to continue with chemotherapy as prescribed.1 Severe cases will usually require hospital treatment for monitoring and nutritional support.2

The launch of this mouthwash complements the earlier launch of Mucodis® Oromucosal Spray in November 2015. The spray is indicated for the treatment of oral mucositis in specific patients after the condition has developed. However, the mouthwash has an indication for the prevention of oral mucositis in patients as they start cancer treatment, enabling its use in a larger population.

Quantum has a specific therapeutic account team in place to support the launch of the Mucodis® range. In discussions with oncology specialists, nurses and pharmacists, a clear medical need amongst patients has been identified for this range of products. Due to this anticipated demand, as with the Mucodis® Oromucosal Spray, the entire first manufacturing batch of Mucodis® mouthwash has been bought by pharmaceutical wholesalers.

It is anticipated that further Mucodis® products will be launched during the financial year ended 31 January 2017.

Andrew Scaife, CEO of Quantum Pharma, commented: "Mucodis® mouthwash is an important addition to the Mucodis® range, not only for Quantum as we establish the Niche Pharmaceutical division in the UK, but for patients undergoing treatment for cancer. We believe the outlook for the Mucodis® range is very positive and we are delighted to be able to offer multi-faceted relief from the commonly experienced side-effects of cancer treatment."

1. http://www.oralcancerfoundation.org/complications/mucositis.php  

2. http://www.nhs.uk/Conditions/mucositis/Pages/Introduction.aspx

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials

Comprising four business units:

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch-made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development as well as clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared, sterile intravenous products, either individually, for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Niche Pharmaceuticals

Comprising three business units:

Colonis® is a product development business, which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full-service contract development specialist with customers across Europe. It specialises in creating added-value products with distinct advantages for patients and health care providers. It also provides full services for the entire development chain - from inception to registration; to post-approval, finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand -- a range of menthol in aqueous creams.

Medication Adherence

Comprises two business units:

Biodose® is a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. Biodose Connect® - a telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.